Eli Lilly and Company (LLY)
| Market Cap | 678.91B |
| Revenue (ttm) | 40.86B |
| Net Income (ttm) | 8.37B |
| Shares Out | 900.43M |
| EPS (ttm) | 9.25 |
| PE Ratio | 81.52 |
| Forward PE | 33.68 |
| Dividend | $6.00 (0.80%) |
| Ex-Dividend Date | Feb 14, 2025 |
| Volume | 2,753,812 |
| Open | 745.58 |
| Previous Close | 742.35 |
| Day's Range | 739.05 - 760.37 |
| 52-Week Range | 624.68 - 972.53 |
| Beta | 0.41 |
| Analysts | Strong Buy |
| Price Target | 980.48 (+30.04%) |
| Earnings Date | Feb 6, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the comp... [Read more]
Financial Performance
In 2023, Eli Lilly's revenue was $34.12 billion, an increase of 19.56% compared to the previous year's $28.54 billion. Earnings were $5.24 billion, a decrease of -16.08%.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $980.48, which is an increase of 30.04% from the latest price.
News
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and Goliath dynamic” in 2024, report says.
Stock Of The Day: Lilly's Strong Support Level Signals Potential Rebound
Shares of Eli Lilly and Company LLY are trading higher after getting pummeled on Friday. The move lower happened after the company announced preliminary sales that were less than expected.
Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer's, Study Shows. What It Means for the Stocks.
Weight-loss medications have exploded in popularity but the health-benefits go beyond obesity.
Eli Lilly: Market Overreacted
Eli Lilly's Q4 FY24 guidance adjustment is due to supply chain factors, not demand, creating an attractive buying opportunity with a 'Buy' rating. Despite a modest 0.6% revenue reduction, LLY still pr...
Dr. Kavita Patel talks impact of GLP-1 price negotiations
Dr. Kavita Patel joins 'Fast Money' to talk what is next for GLP-1 drug makers.
Ozempic, Wegovy among drugs subject to Medicare price controls
The Biden administration released another list of prescriptions drugs that would be subject to price controls. The price controls for the selected drugs will become effective in 2027.
US FDA approves expanded use of Lilly's bowel disease drug
Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's disease, a type of chronic inflammatory bowel disease.
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year Among those who achieved clinical remiss...
Eli Lilly: Big 2025 Ahead, But Execution Risks Exist
Eli Lilly: Big 2025 Ahead, But Execution Risks Exist
Eli Lilly cuts Q4 sales forecast, but analyst remains bullish on stock—here's why
Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 million below the low end of the company's prior guidance and includes $3.5...
Eli Lilly Adjusts Outlook, CEO David Ricks Explains Revenue Shortfall
Just before the JP Morgan healthcare conference, Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth co...
Buy, Sell, Or Hold LLY Stock At $750?
Eli Lilly stock (NYSE: LLY) fell over 6% on Tuesday, January 14, after it announced that the sales of its obesity drugs are seeing slower than anticipated growth. It has adjusted its Q4 revenue foreca...
Watch These Eli Lilly Price Levels as Stock Slumps on Tepid Sales Outlook
Eli Lilly (LLY) shares could remain under the microscope on Wednesday after falling sharply in trade on Tuesday as the pharmaceutical giant lowered its 2024 full-year revenue forecast.
Eli Lilly and Company (LLY) CEO Dave Ricks presents at 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ET Company Participants Dave Ricks - Chairman and CEO Conference Call Participants Chris Schott...
Long-term possibilities in healthcare are unbelievable, says Jim Cramer
'Mad Money' host Jim Cramer looks at several healthcare stocks and shares his perspective on their trajectory in 2025.
Jim Cramer says he supports healthcare stocks for their long-term value
CNBC's Jim Cramer on Tuesday opined on the importance of investing for the long term, telling investors it's wise to evaluate certain pharmaceutical stocks for their growth prospects. "Ask yourself wh...
Buy the weakness in Eli Lilly, says Mizuho Healthcare Strategist Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk how to play Eli Lilly's stock right now.
S&P 500 Gains and Losses Today: Eli Lilly Stock Falls as Sales Outlook Weakens
Major U.S. equities indexes were mixed on Tuesday after the latest Producer Price Index (PPI) data showed a lighter-than-expected uptick in wholesale prices for December. The soft PPI report helped al...
Stock Market Today: Stocks Are Mixed Ahead of CPI
Cool wholesale inflation numbers provide only slight relief before Wednesday's release of December Consumer Price Index data.
Eli Lilly Stock Slumps on Lowered Sales Forecast
Eli Lilly (LLY) shares tumbled Tuesday after the drugmaker lowered its revenue forecast for the 2024 fiscal year.
Final Trades: Reddit, Delta, Thermo Fisher and Eli Lilly
The Investment Committee give you their top stocks to watch for the second half.
Eli Lilly CEO on prospect of insurance companies covering weight loss drugs
Eli Lilly CEO David Ricks discusses the potential of insurance companies covering weight loss drugs saying they will “recognize it's the ultimate prevention medication.”
Eli Lily cuts 2024 revenue guidance by $400M, shares sink 8%
Eli Lilly saw its shares crash in early trade on Tuesday as the pharm major provided its revenue outlook for 2024 and 2025. The pharma major cut its revenue guidance for the year leading to an around ...
Lilly's Zepbound and Mounjaro Sales Miss Estimates Again. The Wobble's Looking Serious.
It was the second consecutive miss for the two closely watched obesity and Type 2 diabetes drugs.